Cutler Group’s Vaxcyte PCVX Stock Holding History

Cutler Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,000	Closed	-$112K	–	4027
2023 Q1	$112K	Buy	+3,000	New	+$127K	0.01%	933

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cutler Group's PCVX Position: Q2 2023 in Review

Cutler Group sold out of Vaxcyte (PCVX) in Q2 2023, closing a stake of 3,000 shares — an estimated $112K sold.

Cutler Group first reported a position in PCVX in Q1 2023 and held it in 1 quarter. The position peaked at $112K in Q1 2023. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

Cutler Group reported no remaining Vaxcyte position as of Q2 2023 after selling out during the quarter.
Cutler Group sold 3,000 Vaxcyte shares in Q2 2023, an estimated $112K.
Cutler Group first reported a position in Vaxcyte in Q1 2023 and held it in 1 quarter.
Cutler Group's Vaxcyte position peaked at $112K in Q1 2023.
197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.